Breaking Through the Stigma as Access Expands to GLP-1s

The Medscape article “Breaking Through the Stigma as Access Expands to GLP-1s” looks at how glucagon-like peptide-1 (GLP-1) medications, originally developed for diabetes and now widely used for obesity and metabolic health, are becoming more accessible to patients, but stigma still clouds conversations between doctors and those who might benefit. As prescriptions for drugs like semaglutide and tirzepatide climb, clinicians point out that overcoming negative perceptions about weight-loss medications and the people who use them is just as important as improving insurance coverage and affordability.

The article also highlights insights from Dr. Evan Nadler, who discusses how early intervention, patient counseling, and destigmatizing obesity care play a critical role in helping patients navigate treatment and achieve better long-term health outcomes.

Read the full article here for more details.